Oppenheimer lowered the firm’s price target on Korro Bio (KRRO) to $90 from $155 and keeps an Outperform rating on the shares following quarterly results. The firm notes KRRO-110/AATD Phase 1/2a REWRITE SAD interim readout remains on track in the second half of 2025. While Oppenheimer’s fundamental outlook on Korro remains intact, negative sector sentiment continues to weigh heavily on early clinical-stage companies with no clinical data; accordingly, the firm increases the discount rate from 30% to 40%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio Reports Q1 2025 Financial Results
- Korro Bio price target lowered to $53 from $130 at H.C. Wainwright
- Korro Bio price target lowered to $100 from $115 at H.C. Wainwright
- Strategic Workforce Restructuring and Clinical Advancements Justify Buy Rating for Korro Bio
- Korro Bio reports Q1 EPS ($2.49), consensus ($2.62)